Natco Pharma Limited has informed the Exchange regarding a press release dated March 20, 2026, titled "NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma has launched a generic version of Semaglutide, a GLP-1 therapy used for type 2 diabetes, in India on March 21, 2026 — the very first day of the drug's patent expiry. The company received CDSCO approval in February 2026 to manufacture and market the product. Multi-dose vials are priced at MRP INR 1,290 per month (for 2mg/1.5ml and 4mg/3ml strengths) and INR 1,750 for the 8mg/3ml strength, marketed under the brand names SEMANAT and SEMAFULL. A pen device variant is expected to launch in April 2026 at INR 4,000–4,500 per month. Natco claims it is the first company to offer generic Semaglutide in multi-dose vial form in India, priced approximately 90% lower than the innovator's brand, and is also offering co-marketing rights to third parties.
This is a positive first-to-market generic launch of a high-demand diabetes/obesity drug on Day 1 of patent expiry, which could translate into meaningful new revenue for Natco. The aggressive pricing strategy (90% cheaper than the innovator) positions the company to capture significant market share, though actual revenue impact will depend on uptake and volume. The stock may see positive sentiment in the short term.